On 10 October, Biotronik announced the launch of the new Idova 7 implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators (CRT-Ds).
According to a company release, the Idova 7 technology offers ultrahigh-energy therapy without compromising on short charge times (10sec), smaller size (34cc), and longevity of more than 11 years.
Idova 7 is approved for magnetic resonance imaging (MRI), the company states that the device is engineered to increase the success rate of the first shock and reduce the need for subsequent shocks.
“Ideally, a patient’s heart would react the same way to ICD therapy in real life as it would when tested after implantation. But that is not so often the case,” said Clemens Steinwender, General Hospital Linz, Austria. “If I can give my patients that extra energy at the first shock, then I can assure them they are on the safe side.”
First implanters of the Idova 7 series are:
- Clemens Steinwender, General Hospital Linz, Austria
- Fabrizio Caravati, Hospital Fondazione Macchi of Varese, Italy
- Paolo Bonfanti, Hospital Fondazione Macchi of Varese, Italy
